Percutaneous Mitral Valve Repair versus Optimal Medical Therapy in Patients with Functional Mitral Regurgitation: A Systematic Review and Meta-Analysis
Table 2
Characteristics of the included studies.
Author (year)
Total Participants
Participants
Participants
Follow-up, weeks
Primary endpoints
(# of FMR)
Treatment Group
Control Group
Velazquez, 2015
478 (415 FMR)
239
239
48
All-cause mortality
Asgar, 2016
92 (45 FMR)
50
42
144
All-cause mortality; Cost-effectiveness metrics
Armeni, 2016
383 (383 FMR)
232
151
48
Cost-effectiveness metrics
Giannini, 2016
120 (NR)
60
60
48
All-cause mortality
Geis, 2017
155 (124 FMR)
86
69
48
Cardiac remodeling metrics (LVEF, LVESD)
Obaida, 2018
304 (304 FMR)
152
152
240
Composite: all-cause mortality and HF hospitalizations
Kortlandt, 2018
863 (593 FMR)
568
295
96
All cause mortality
Stone, 2018
614 (614 FMR)
302
312
96
HF hospitalizations at 24 months, device related complications at 12 months
FMR: functional mitral regurgitation; LVEF: left ventricular ejection fraction; LVESD: left ventricular end systolic diameter
